Business Description
Oryzon Genomics SA
ISIN : ES0167733015
Compare
Compare
Traded in other countries / regions
ORY.SpainORN.GermanyORYZF.USA0RDB.UKORY.Mexico IPO Date
2016-07-06Description
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.9 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.17 | |||||
| Debt-to-EBITDA | -3.37 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 5.3 | |||||
| 3-Year EPS without NRI Growth Rate | 3.2 | |||||
| 3-Year FCF Growth Rate | 2.3 | |||||
| 3-Year Book Growth Rate | -2.3 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.57 | |||||
| 9-Day RSI | 44.5 | |||||
| 14-Day RSI | 48.78 | |||||
| 6-1 Month Momentum % | -5.91 | |||||
| 12-1 Month Momentum % | -6.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.87 | |||||
| Quick Ratio | 0.87 | |||||
| Cash Ratio | 0.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.9 | |||||
| Shareholder Yield % | 4.73 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -4.38 | |||||
| ROA % | -3.22 | |||||
| ROIC % | -2.55 | |||||
| ROC (Joel Greenblatt) % | -771.53 | |||||
| ROCE % | -4.78 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.44 | |||||
| EV-to-EBIT | -29.06 | |||||
| EV-to-Forward-EBIT | -37.41 | |||||
| EV-to-EBITDA | -30.16 | |||||
| EV-to-Forward-EBITDA | -38.99 | |||||
| EV-to-Forward-Revenue | 18.47 | |||||
| EV-to-FCF | -8.12 | |||||
| Earnings Yield (Greenblatt) % | -3.44 | |||||
| FCF Yield % | -12.47 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Oryzon Genomics SA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.057 | ||
| Beta | 130.45 | ||
| Volatility % | 19.78 | ||
| 14-Day RSI | 48.78 | ||
| 14-Day ATR (€) | 0.045817 | ||
| 20-Day SMA (€) | 1.95135 | ||
| 12-1 Month Momentum % | -6.37 | ||
| 52-Week Range (€) | 1.586 - 2.315 | ||
| Shares Outstanding (Mil) | 62.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Oryzon Genomics SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Oryzon Genomics SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Oryzon Genomics SA Frequently Asked Questions
What is Oryzon Genomics SA(STU:ORN)'s stock price today?
The current price of STU:ORN is €1.89. The 52 week high of STU:ORN is €2.32 and 52 week low is €1.59.
When is next earnings date of Oryzon Genomics SA(STU:ORN)?
The next earnings date of Oryzon Genomics SA(STU:ORN) is 2024-05-31 Est..
Does Oryzon Genomics SA(STU:ORN) pay dividends? If so, how much?
Oryzon Genomics SA(STU:ORN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers